Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 118   

Articles published

JNJ 103.13 +0.50 (0.49%)
price chart
Johnson & Johnson to Begin Testing Ebola Vaccine in January
Johnson & Johnson said it would begin testing an Ebola-virus vaccine in humans in January and could have 250,000 doses available in May, if health authorities deem it safe and promising enough to distribute more broadly.
Johnson & Johnson plans Ebola vaccine testing  KSN-TV
Testing for Ebola Vaccines to Start Soon, WHO Says  New York Times
Related articles »  
Johnson & Johnson's DePuy wins first trial over Pinnacle hips
NEW YORK/DALLAS (Reuters) - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopedics unit were defective.
Johnson & Johnson (JNJ) Stock Rises Today Following Texas Lawsuit Dismissal  TheStreet.com
Johnson & Johnson Wins First Pinnacle Hip Implant Trial  Bloomberg
Related articles »  
Johnson & Johnson Recalls Contaminated Xarelto
Microbial contamination in samples of the blockbuster blood thinner Xarelto - used to prevent blood clots and strokes - caused Johnson & Johnson's Janssen unit to recall 13,500 bottles of the drug this week. The recall comes shortly after several new ...
Related articles »  
Ebola: Johnson & Johnson to start vaccine trials in January
Johnson & Johnson is to start testing its Ebola vaccine candidate in January after the World Health Organisation (WHO) and world leaders asked it and other companies to accelerate their research programmes.
Related articles »  
5 Things Johnson & Johnson's Management Wants You to Know
Earlier this month, healthcare conglomerate Johnson & Johnson (NYSE: JNJ ) reported its third-quarter earnings results, and it was once again business as usual.
Johnson & Johnson Share price: Healthcare Aristocrat Leads Recovery on ...  iNVEZZ
Related articles »  
Is Johnson & Johnson's Worst Nightmare Becoming Reality?
Johnson & Johnson (NYSE: JNJ ) has been one of the few top healthcare companies to post strong growth within its pharmaceutical segment this year.
Related articles »  
Why Johnson & Johnson (JNJ) Stock Is Higher Today
NEW YORK (TheStreet) -- Shares of Johnson & Johnson (JNJ) are up 1.61% to $101.98 in pre-market trade after it was reported this morning that the company plans to have 250,000 doses of an experimental Ebola vaccine ready for use in clinical trials in ...
Market Reaction To Johnson & Johnson's Earnings Is Justified
Johnson & Johnson's stock price fell sightly following its Q3 2014 earnings announcement despite the company beating consensus estimates and keeping the full year outlook the same.
TMC confirms Johnson & Johnson incubator
Johnson & Johnson has similar incubators in San Diego, San Francisco and Boston. And although Houston has long been known as a medical hub, with nearly $1 billion worth of research at the Texas Medical Center annually, something's been missing.
Johnson & Johnson: Growth-Growth-Growth; Win-Win-Win - Part IV (JNJ)
For Part III, I provided sensitivity modeling of both investment value growth and dividend growth under a range of share price and dividend growth projections at a constant PE ratio.